NewAmsterdam Pharma Co N.V. (NAMS): Capital Expenditures

Annual figures by period end, from SEC filings.

$246.0K

Year ended 2025-12-31

$260.0K

Trailing 12 months to 2026-06-30

+3.6%

3-year compound annual growth

2021-12-31 Capital Expenditures (USD) 2025-12-31

Period ended	Capital Expenditures	Change YoY	Source filing
2025-12-31	$246.0K	-63.4%	2026-02-18, From 2025-01-01
2024-12-31	$672.0K	n/m	2026-02-18, From 2024-01-01
2023-12-31	$24.0K	-89.1%	2026-02-18, From 2023-01-01
2022-12-31	$221.0K	+820.8%	2025-02-26, From 2022-01-01
2021-12-31	$24.0K	n/a	2024-02-28, From 2021-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Capital Expenditures	Change YoY
NewAmsterdam Pharma Co N.V. (NAMS)	2025-12-31	$246.0K	-63.4%
Alumis Inc. (ALMS)	2025-12-31	$653.0K	-62.3%
CASI Pharmaceuticals, Inc. (CASIF)	2025-12-31	$16.0K	-92.8%
Evofem Biosciences, Inc. (EVFM)	2025-12-31	$5.0K	-64.3%
Entrada Therapeutics, Inc. (TRDA)	2025-12-31	$1.04M	-67.0%
Sol-Gel Technologies Ltd. (SLGL)	2025-12-31	$47.0K	n/m
Celularity Inc (CELU)	2024-12-31	$161.0K	-84.6%
Cue Biopharma, Inc. (CUE)	2025-12-31	$177.0K	+168.2%
Foghorn Therapeutics Inc. (FHTX)	2025-12-31	$50.0K	-94.5%

Compare NAMS, ALMS, CASIF, EVFM side by side · Screen every company in Pharmaceutical Preparations ↗